The 1st CEO Meeting of the Term (2022-24) was held online on 11 July 2022. More than 20 CEOs and directors from our member companies joined to meet the new HKAPI Board, and exchanged views on the future directions of the Association.
The Hong Kong Association of the Pharmaceutical Industry (HKAPI) is delighted to be one of the supporting organizations of the hybrid event hosted by InvestHK - “The Journey of Biotech Innovation and Investment in Hong Kong” on 7 July.
To ensure members have a thorough understanding of the relevant laws, regulations and Codes regarding medicinal material communicating to the public via different mediums, the HKAPI organises an event with law enforcement authorities and experts to explain the law and its enforcement.
The High-Level Steering Committee on Antimicrobial Resistance was set up in 2016 to call for collaboration, synergy and cross-fertilisation of all professional sectors under the "One Health" framework in response to AMR. Ms. Sabrina Chan, the Senior Executive Director of HKAPI has been a member of the Steering Committee since the establishment of the Committee.
To help HKAPI members understand more about the operation of DHC and opportunities for the pharmaceutical industry, the Public-Private Partnership task force organized a Sharing Session on April 27, 2022.
The Hong Kong Association of The Pharmaceutical Industry held its 54th Annual General Meeting on 30 March 2022 and delighted to announce the formation of the New Board (2022-2024) with the following members: